TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05056727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Zirconium Cyclosilicate (SZC)
Description: Powder for oral suspension in a sachet. Unit dose strength: 5 or 10 g SZC. Single dose will consist of 1-3 sachets.~During Initiation Phase:~* S-K \> 5 to ≤ 6.5 mmol/L (measured by L-Lab): Single dose contains 10 g SZC that should be suspended in 45 mL of water. The 10 g SZC single dose should be administered three times daily for up to 72 hours until normokalaemic (S-K 3.5-5.0 mmol/L); the total daily dose is 30 g SZC.~* S-K ≥ 3.5 to ≤ 5 mmol/L (measured by L-Lab): Single dose contains 5 g SZC that should be suspended in 45 mL of water and administered once daily for 48 hours.~During Run-in and Maintenance Phases:~- Single dose contains 5 g SZC administered every other day or 5, 10, or 15 g SZC administered once daily that should be suspended in 45 mL of water.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Powder for oral suspension in a sachet. Placebo to match 5 or 10 g. Single dose will consist of 1-3 sachets.~During Maintenance Phase:~- Single dose contains 5 g placebo administered every other day or 5, 10, or 15 g placebo administered once daily that should be suspended in 45 mL of water.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lisinopril
Description: Tablet for oral administration. Unit dose strength: 2.5, 5, 10 or 20 mg. Dosage level: 5, 10, 20, or 40 mg administered once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisinopril
Description: Tablet for oral administration. Unit dose strength: 2.5, 5, 10 or 20 mg. Dosage level: 5, 10, 20, or 40 mg administered once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Valsartan
Description: Tablet or capsule for oral administration. Unit dose strength: 40, 80 or 160 mg. Dosage level: 40, 80, 160, or 320 mg administered once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: Tablet or capsule for oral administration. Unit dose strength: 40, 80 or 160 mg. Dosage level: 40, 80, 160, or 320 mg administered once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Irbesartan
Description: Tablet for oral administration. Unit dose strength: 75, 150 or 300 mg. Dosage level: 75, 150, or 300 mg administered once daily.~The study is designed to use valsartan as the selected ARB therapy adjunct to SZC. However, if an actual shortage of valsartan in a local market jeopardises the ability of participants to enter or continue in the study, valsartan can be temporarily substituted with irbesartan until the shortage of valsartan is resolved.
Study: NCT06281158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-DNL343
Description: Single dose
Study: NCT04424030

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Standard echocardiography exam performed as part of clinical management.

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance imaging (MRI)
Description: Standard comprehensive cardiac MRI exam of the heart performed as part of clinical management.

Intervention type: DIAGNOSTIC_TEST
Intervention: Computed tomography (CT)
Description: ECG-triggered, contrast-enhanced CT scan of the heart performed for research purposes in eligible study participants.
Study: NCT06024707

Intervention type: DRUG
Intervention: Biological Drug
Description: This intervention is part of regular treatment, subjects will be included if they get this treatment.
Study: NCT06314412

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stoller's Afferent Nerve Stimulation (SANS)
Description: 15 sessions of SANS (5 sessions/week for 3 weeks)
Study: NCT04856059

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Cardiac MRI, ECG/Holter and Blood Biomarkers
Description: Cardiac MRI including T1/T2 mapping, ECG and blood biomarker evaluation will be performed at baseline and follow-up
Study: NCT05056727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan
Description: Tablet for oral administration. Unit dose strength: 75, 150 or 300 mg. Dosage level: 75, 150, or 300 mg administered once daily.~The study is designed to use valsartan as the selected ARB therapy adjunct to SZC. However, if an actual shortage of valsartan in a local market jeopardises the ability of participants to enter or continue in the study, valsartan can be temporarily substituted with irbesartan until the shortage of valsartan is resolved.
Study: NCT05716776

Intervention type: DIAGNOSTIC_TEST
Intervention: Optical coherence tomography (OCT)
Description: Measurement of retinal nerve fibre layer (RNFL) thickness using optical coherence tomography

Intervention type: DIAGNOSTIC_TEST
Intervention: Optical coherence tomography (OCT)
Description: Measurement of retinal nerve fibre layer (RNFL) thickness using optical coherence tomography

Intervention type: DIAGNOSTIC_TEST
Intervention: Optical coherence tomography (OCT)
Description: Measurement of retinal nerve fibre layer (RNFL) thickness using optical coherence tomography
Study: NCT05090267

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic Supplement
Description: Participants will take a probiotic supplement or placebo for 90 days.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Vagal Nerve Stimulation (tVNS)
Description: Participants will use a non-invasive stimulator 1 hour daily for 30 days. This stimulator is placed around the ear similar to headphones and produces a very mile electric current. This wellness device is safe to use and painless. Some describe the sensation to be a slight tingle up to a small itch.
Study: NCT06180863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral azacitidine (CC-486)
Description: Oral azacitidine is indicated for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy.
Study: NCT05445167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KLH-2109
Description: Oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration
Study: NCT04909138

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DRG stimulation 20 Hz 30/90
Description: Stimulation delivered at 20 Hz and 30 seconds ON, 90 seconds OFF

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DRG stimulation 5 Hz 30/90
Description: Stimulation delivered at 5 Hz and 30 seconds ON, 90 seconds OFF
Study: NCT04665362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant oncolytic virus M1, anti PD-1 antibody, Apatinib
Description: Drug: Recombinant oncolytic virus M1~Recombinant oncolytic virus M1 is administered intravenously 1×109 CCIC50 once daily on day1-5, every 28 day cyle.~Other name：M1-c6v1~Drug：Anti-PD-1 antibody~Anti-PD-1 antibody is administered intravenously 200 mg once every 2 weeks.~Other names：SHR-1210, Camrelizumab~Drug: Apatinib~Apatinib is administered orally 250mg once daily.~Other name: Apatinib
Study: NCT05200325

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational materials for TissueCypher
Description: These materials detail what the test does, how it is used, the validity and specifications of the test, and how to read its test report.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational materials for TissueCypher
Description: These materials detail what the test does, how it is used, the validity and specifications of the test, and how to read its test report.
Study: NCT06023810

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Watson's human care theory-based motivational interviewing method
Description: The Motivational Interviewing Program based on Watson's Theory of Human Caring will be conducted over an 8-week period, with sessions taking place once a week. The initial session will have a duration of 60 minutes, while the subsequent weekly sessions will last for 30 minutes
Study: NCT05160571

Intervention type: DEVICE
Intervention: Ion Endoluminal System
Description: Ion Endoluminal Procedure for pulmonary nodule
Study: NCT05079594

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mother voice
Description: Five minutes before the procedure, the mother's voice recording will be played to the baby and the speaker will be placed 30 cm away from the baby. The baby's comfort level will be evaluated by the researcher using the Neonatal Comfort Behavior Scale 2 minutes before the procedure begins. Physiological values of the baby will be noted by the researcher 1 minute before the procedure.As soon as the heel blood procedure is completed, the baby's physiological values and comfort level will be noted by the Newborn Comfort Behavior Scale by the researcher. After the procedure, the recording will continue to be played until the baby's mother's voice returns to the basal values. Physiological values and comfort levels of the baby will be noted by the researcher 1 minute and 2 minute after the procedure. 2 minutes after the procedure, the baby's comfort level will be evaluated by the researcher using the Neonatal Comfort Behavior Scale.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White noise
Description: Before Operation The decibel meter will be set to an average of 50-60 dB and the speakers will be played at a distance of 30 cm.~Intervention in this group will be made at the elevation. White noise will be played five minutes before the procedure.The baby's comfort level and physiological values will be evaluated by the researcher using the Neonatal Comfort Behavior Scale 2 minutes before the procedure begins.~Order of Operation As soon as the heel blood procedure is completed, the baby's physiological values and comfort level will be noted by the Newborn Comfort Behavior Scale by the researcher.~Post-Processing After the procedure, white noise will continue to be listened to until the baby's physiological values return to basal values. Physiological values and baby's comfort level of the baby will be noted by the researcher 1 minute and 2 minute after the heel blood collection is completed.
Study: NCT05917860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Degarelix is injected subcutaneously into the fatty tissue of the abdomen. A typical protocol consists of a starting dose of 240 mg with a maintenance dose of 80 mg administered every 28 days. In this study, one starting dose and two maintenance doses of Degarelix will be administered between baseline and TULSA treatment in accordance with the terms of Degarelix marketing authorizations.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI-guided transurethral ultrasound ablation (TULSA)
Description: MRI-guided transurethral ultrasound ablation (TULSA) (TULSA-PRO, Profound Medical Inc., Toronto, Canada) will be used to deliver whole-prostate gland treatment in accordance with the terms of TULSA marketing authorizations. The treating physicians will contour the entire prostate gland for a whole gland ablation.
Study: NCT05678686

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Routine Exercise Group
Description: Exercises (tongue-palate exercises, tongue base exercises, Masako Maneuver, Mendelson Maneuver, Effortful Swallowing, Supraglottic exercises, thermal tactile stimulation) will be performed 2 days a week for 8 weeks, in total 16 sessions and these exercises applied by the physiotherapist.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: PNF Exercise
Description: In addition to the practices in the control group, head-neck PNF(Proprioceptive Neuromuscular Facilitation) movement patterns will be applied to both movement patterns by the physiotherapist using the combined isotonic contraction technique ), 2 days a week for 8 weeks, in total 16 sessions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: CTAR Exercise
Description: In addition to the practices in the control group, CTAR exercises will be applied in the presence of a physiotherapist, 2 days a week for 8 weeks, a total of 16 sessions. In the CTAR exercise, the patient is asked to flexion and extension the neck by pressing a standard size and inflatable rubber ball placed under his chin against his sternum. Patients will be asked to do the exercise protocol, which consists of isometric and isotonic components.
Study: NCT05082285

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MenABCWY-2Gen low dose vaccine
Description: MenABCWY-2Gen low dose vaccine is administered intramuscularly in the upper thigh region of the right leg as 3 doses to participants in study Part I, Step 1 and study Part II.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MenABCWY-2Gen high dose vaccine
Description: MenABCWY-2Gen high dose vaccine is administered intramuscularly in the upper thigh region of the right leg as 3 doses to participants in study Part I, Step 2 and study Part II.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MenABCWY-1Gen vaccine
Description: MenABCWY-1Gen vaccine is administered intramuscularly in the upper thigh region of the right leg as 3 doses to participants in study Part II.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: MenB vaccine
Description: MenB vaccine is administered intramuscularly in the upper thigh region of the right leg as 3 doses to participants in study Part I, Step 1 and Step 2 and study Part II.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: MenACWY-TT vaccine
Description: MenACWY-TT vaccine is administered intramuscularly in the lower thigh region of the right leg as 3 doses to participants in study Part I, Step 1 and Step 2 and study Part II.
Study: NCT05913869

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Mindfulness Based Stress Reduction
Description: Based on the UMASS curriculum developed by Dr. Jon Kabat-Zinn, it is an 8-week mindfulness stress reduction program. It is a skill-based psychoeducational program that meets 2 hours for 8 weeks to discuss stress, cognition and health. The weekly intervention includes didactic presentations, class dialogue and inquiry, formal (e.g., body scan, walking meditation) and informal (e.g., awareness of pleasant and unpleasant events, interpersonal communications, etc.) mindfulness practice.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online Mindfulness Based Stress Reduction
Description: Based on the UMASS curriculum developed by Dr. Jon Kabat-Zinn, it is an 8-week mindfulness stress reduction program. It is a skill-based psychoeducational program that meets 2 hours for 8 weeks to discuss stress, cognition and health. The weekly intervention includes didactic presentations, class dialogue and inquiry, formal (e.g., body scan, walking meditation) and informal (e.g., awareness of pleasant and unpleasant events, interpersonal communications, etc.) mindfulness practice.
Study: NCT05563649

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Guided Self-Help-Family-based Treatment
Description: GSH-FBT consists of 10 20-minute sessions for parents only over 9 months. Sessions follow an online curriculum of 65 short videos: 62 with an expert clinician instructing parents on the principles of FBT, and 3 reflections from an adolescent who recovered from AN and completed FBT. Each lecture series contains an introduction orienting the viewer to the videos, 5-9 short videos (\< 7 minutes each), and assigned reading from the parent education manual Help Your Teenager Beat an Eating Disorder. Three lectures include additional resources for parents (e.g., Academy of Eating Disorder (AED) Medical Management Guidelines). Homework assignments are included with some lectures (e.g., strategies to help the child eat during meals, practice making calorically dense meals). In line with GSH approaches, coach-therapists direct parents, to watch or re-watch specific video content contained in the online learning material related to their questions rather than direct behavioral change.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FBT via Videoconferencing
Description: 15 60-minute sessions of 3-phase manualized FBT modified for videoconferencing will be delivered to participants randomized to this treatment by therapists trained in FBT. The first phase encourages parental management of weight restoration (approximately 8 weekly sessions); the second phase promotes a developmentally appropriate transition back to adolescent management of weight restoration and maintenance under parental supervision (approximately 4 bi-weekly sessions), and the third phase focuses on adolescent development (approximately 3 monthly sessions). Each session consists of 10 minutes with the adolescent individually to discuss progress and the adolescent's perspective on treatment, followed by 50 minutes with the entire family.
Study: NCT05256810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-XDH
Description: ALN-XDH administered by SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-XDH
Description: ALN-XDH administered by SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-XDH
Description: ALN-XDH administered by SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-XDH
Description: ALN-XDH administered by SC injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered by SC injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered by SC injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered by SC injection
Study: NCT05783999

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vibra plus
Description: the device is applied to the patient's lower limbs and generates an active flow of vibrations that may reduce fatigue
Study: NCT04969276

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Inactivated Influenza High Dose
Description: Sterile suspension for injection in a pre-filled syringe Intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quadrivalent Inactivated Influenza High Dose
Description: Sterile suspension for injection in a pre-filled syringe Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 mRNA Vaccine (nucleoside modified)
Description: Sterile suspension (white to off-white) in multidose vial Intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: COVID-19 mRNA Vaccine (nucleoside modified)
Description: Sterile suspension (white to off-white) in multidose vial Intramuscular injection
Study: NCT06547047

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speed, Agility, and Quickness (SAQ) Training
Description: The SAQ training will include exercises designed to improve speed, agility, and quickness, such as ladder drills, cone drills, sprint drills, and reaction drills.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Regular Training
Description: Participants in the control group will follow a standard soccer training regimen, which includes general conditioning exercises, skill drills, and tactical training.
Study: NCT06050356

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: i.d. placebo
Description: Participants will receive one i.d. injection of placebo on Day 1
Study: NCT04875871

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Particle radiotherapy
Description: Partial radiotherapy targeting the hypoxic tumor segment

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Particle radiotherapy
Description: Partial radiotherapy targeting the hypoxic tumor segment

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging
Description: For treatment planning as well as for follow-up radiological tumor assessment.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging
Description: For treatment planning as well as for follow-up radiological tumor assessment.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Computertomography
Description: For treatment planning as well as for follow-up radiological tumor assessment.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Computertomography
Description: For treatment planning as well as for follow-up radiological tumor assessment.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Copper-64-Diacetyl-bis (N4-methylthiosemicarbazone) Positron Emission Tomography-Computer Tomography (64Cu-ATSM-PET-CT)
Description: For the definition of the hypoxic tumor segment in treatment planning.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Copper-64-Diacetyl-bis (N4-methylthiosemicarbazone) Positron Emission Tomography-Computer Tomography (64Cu-ATSM-PET-CT)
Description: For the definition of the hypoxic tumor segment in treatment planning.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18-F-FluorDesoxyGlukose Positron Emission Tomography-Computer Tomography (18F-FDG-PET-CT)
Description: For follow-up radiological tumor assessment.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18-F-FluorDesoxyGlukose Positron Emission Tomography-Computer Tomography (18F-FDG-PET-CT)
Description: For follow-up radiological tumor assessment.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Evaluation before treatment-start, during treatment and follow-up period.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Evaluation before treatment-start, during treatment and follow-up period.
Study: NCT06050356

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intranasal H107e
Description: Participants will receive one i.n. administration of 30 µg H107e (full dose intranasal H107e) on Day 211

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intranasal H107e
Description: Participants will receive one i.n. administration of 30 µg H107e (full dose intranasal H107e) on Day 211

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal H107e
Description: Participants will receive one i.n. administration of 30 µg H107e (full dose intranasal H107e) on Day 211

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal H107e
Description: Participants will receive one i.n. administration of 30 µg H107e (full dose intranasal H107e) on Day 211
Study: NCT04974541

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heart Health Yoga
Description: Yoga-based digital intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychosocial education
Description: Standard psychosocial education component

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychosocial education
Description: Standard psychosocial education component